Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5h-(1)benzopyrano(4,3-c)quinolin-2-ol, 5-(4-(2-(3-(fluoromethyl)-1-azetidinyl)ethoxy)phenyl)-8-(trifluoromethyl)-, (5r)-
2. 5h-(1)benzopyrano(4,3-c)quinolin-2-ol, 5-(4-(2-(3-(fluoromethyl)-1-azetidinyl)ethoxy)phenyl)-8-(trifluoromethyl)-, (5r)-, Compd. With 4-methylbenzenesulfonate (1:1)
3. Imlunestrant Tosylate
4. Ly3484356
1. Imlunestrant [usan]
2. Unii-9cxq3pf69u
3. 9cxq3pf69u
4. Ly3484356
5. 2408840-26-4
6. (5r)-5-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5h-(1)benzopyrano(4,3-c)quinolin-2-ol
7. 5h-(1)benzopyrano(4,3-c)quinolin-2-ol, 5-(4-(2-(3-(fluoromethyl)-1-azetidinyl)ethoxy)phenyl)-8-(trifluoromethyl)-, (5r)-
8. Imlunestrant [inn]
9. Schembl22002569
10. Bdbm443429
11. Glxc-26209
12. Us10654866, Example 1a
13. Ex-a6123
14. Who 12039
15. Ly-3484356 [who-dd]
16. Hy-145572
17. Cs-0376104
18. Ly-3484356
| Molecular Weight | 524.5 g/mol |
|---|---|
| Molecular Formula | C29H24F4N2O3 |
| XLogP3 | 6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 6 |
| Exact Mass | 524.17230528 g/mol |
| Monoisotopic Mass | 524.17230528 g/mol |
| Topological Polar Surface Area | 54.8 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 0 |
| Complexity | 788 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Imlunestrant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Imlunestrant, including repackagers and relabelers. The FDA regulates Imlunestrant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Imlunestrant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Imlunestrant supplier is an individual or a company that provides Imlunestrant active pharmaceutical ingredient (API) or Imlunestrant finished formulations upon request. The Imlunestrant suppliers may include Imlunestrant API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Imlunestrant as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Imlunestrant API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Imlunestrant as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Imlunestrant and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Imlunestrant NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Imlunestrant suppliers with NDC on PharmaCompass.
Imlunestrant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Imlunestrant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Imlunestrant GMP manufacturer or Imlunestrant GMP API supplier for your needs.
A Imlunestrant CoA (Certificate of Analysis) is a formal document that attests to Imlunestrant's compliance with Imlunestrant specifications and serves as a tool for batch-level quality control.
Imlunestrant CoA mostly includes findings from lab analyses of a specific batch. For each Imlunestrant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Imlunestrant may be tested according to a variety of international standards, such as European Pharmacopoeia (Imlunestrant EP), Imlunestrant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Imlunestrant USP).
LOOKING FOR A SUPPLIER?
